- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | AQUAPORIN A/S: RESURGENCE: Aquaporin joins project for innovative water treatment solutions | 1 | Cision News | ||
| 08.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.04.2024 | 200 | Xetra Newsboard | Das Instrument X2Y IT0005495871 YOLO GROUP S.P.A. O.N. EQUITY wird ex Kapitalmassnahme gehandelt am 08.04.2024 The instrument X2Y IT0005495871 YOLO GROUP S.P.A. O.N. EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 05.04. | AQUAPORIN A/S: Notice convening the annual general meeting 2024 | 1 | Cision News | ||
| 05.04. | Aquaporin A/S: Aquaporin publishes prospectus and initiates rights issue | 189 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY... ► Artikel lesen | |
| 05.04. | Nasdaq Copenhagen A/S: Aquaporin A/S - rights issue, admission to trading and official listing of subscription rights | 225 | GlobeNewswire | Subscription rights in Aquaporin A/S will be admitted to trading and official
listing on Nasdaq Copenhagen as per 8 April 2024. As of the same date, ISIN
DK0061555109 (AQP) will be traded excl. of subscription... ► Artikel lesen | |
| 05.04. | Aquaporin A/S: Aquaporin announces full-year 2023 results, with year-on-year revenue growth of 95% | 260 | PR Newswire | Aquaporin A/S, Nymøllevej 78, DK-2800 Kongens Lyngby, aquaporin.com, Company registration no.: DK28315694Company announcementNo. 06/2024
COPENHAGEN, Denmark, April 5, 2024 /PRNewswire/... ► Artikel lesen | |
| 03.04. | AQUAPORIN A/S: Aquaporin will host webcast on April 5 to present full-year 2023 results | 1 | Cision News | ||
| 22.03. | Business transacted at the extraordinary general meeting of Aquaporin A/S | 2 | Cision News | ||
| 05.03. | AQUAPORIN A/S: Aquaporin joins KitNewCare to enhance kidney healthcare across Europe | 3 | Cision News | ||
| 29.02. | AQUAPORIN A/S: Notice to convene Extraordinary General Meeting | 1 | Cision News | ||
| 29.02. | AQUAPORIN A/S: Update on rights issue process, extraordinary general meeting, and financial calendar | 1 | Cision News | ||
| 02.02. | AQUAPORIN A/S: Aquaporin announces changes in Executive Management Team | 2 | Cision News |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIO-PATH | 4,200 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Expands Global Patent Portfolio | HOUSTON, April 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 35,120 | +4,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session Nello Mainolfi, Founder, President... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,310 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 9,450 | 0,00 % | Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts | ||
| CABALETTA BIO | 13,970 | -7,79 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| JANUX THERAPEUTICS | 48,850 | 0,00 % | Janux a new buy at Jones on lead assets for solid tumors | ||
| DAY ONE BIOPHARMACEUTICALS | 15,750 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress | PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,400 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| ARCELLX | 54,52 | +1,81 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
| NUVALENT | 63,00 | 0,00 % | Jefferies starts Nuvalent at buy, cites lung cancer drug candidates | ||
| VERA THERAPEUTICS | 39,510 | -1,25 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 23,030 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, March 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,650 | -4,71 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| IMMUNOVANT | 28,320 | 0,00 % | Immunovant, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ADMA BIOLOGICS | 6,200 | +2,65 % | ADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM | FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for... ► Artikel lesen |
AQUAPORIN A/S gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,010 Euro und damit +2,29 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
